PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

The anti-PD-L1 monoclonal antibody (mAb) targeting PD-1/PD-L1 immune checkpoint has achieved outstanding results in clinical application and has become one of the most popular anti-cancer drugs. The mechanism of molecular recognition and inhibition of PD-L1 mAbs is not yet clear, which hinders the s...

Full description

Bibliographic Details
Main Authors:	Xin Sun, Xiao Yan, Wei Zhuo, Jinke Gu, Ke Zuo, Wei Liu, Li Liang, Ya Gan, Gang He, Hua Wan, Xiaojun Gou, Hubing Shi, Jianping Hu
Format:	Article
Language:	English
Published:	MDPI AG 2018-07-01
Series:	International Journal of Molecular Sciences
Subjects:	PD-1/PD-L1 monoclonal antibody MD simulation inhibitory mechanism antibody design
Online Access:	http://www.mdpi.com/1422-0067/19/7/1984

Similar Items

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
by: Vishwanatha R. A. P. Reddy, et al.
Published: (2019-12-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020-09-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
by: Yuan Hong, et al.
Published: (2021-03-01)

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
by: Wu Ye, et al.
Published: (2021-09-01)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
by: Yongshu Li, et al.
Published: (2016-07-01)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
by: Mariacarmela Santarpia, et al.
Published: (2020-06-01)

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
by: Katrijn Broos, et al.
Published: (2019-06-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary
by: Simon Wabitsch, et al.
Published: (2021-01-01)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
by: Hyun Tae Lee, et al.
Published: (2019-03-01)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
by: Giuseppe Bellastella, et al.
Published: (2021-08-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
by: Hideto Tamura, et al.
Published: (2020-04-01)

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
by: Ieva Saulite, et al.
Published: (2020-01-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
by: Xu S, et al.
Published: (2018-12-01)

Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
by: Andrey Kulikov, et al.
Published: (2021-08-01)

BCD-100 - first russian PD-1 inhibitor
by: S A Tyulyandin, et al.
Published: (2017-09-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

mRNA EXPRESSION OF PD-1, PD-L1, AND IMMUNOTHERAPY IN BLADDER CANCER
by: Muhammad Puteh Mauny, et al.
Published: (2021-07-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
by: Xueping Wang, et al.
Published: (2020-05-01)

A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone
by: Haiming YU, et al.
Published: (2021-07-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)